Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2024 09:35 ET | Source: Immix Biopharma, Inc.

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell...
March 20, 2023 06:30 ET | Source: Future Market Insights Global and Consulting Pvt. Ltd.

AL Amyloidosis Therapeutics Market is projected to rise at a 7.3% CAGR until 2033, being valued at US$ 4.56 billion | Future Market Insights, Inc.

NEWARK, Del, March 20, 2023 (GLOBE NEWSWIRE) -- The global AL amyloidosis therapeutics market is expected to be worth US$ 2.25 billion by the year of 2023. The market, which is estimated to be worth...
May 24, 2021 20:59 ET | Source: Telix Pharmaceuticals Limited

TLX66 Meets Study Objectives in Patients with AL Amyloidosis

MELBOURNE, Australia and SOUTHAMPTON, United Kingdom, May 25, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company’s bone marrow...
March 01, 2021 08:00 ET | Source: Caelum Biosciences, Inc.

Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month

BORDENTOWN, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases, today...
February 01, 2021 16:15 ET | Source: Prothena Corporation plc

Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA

Significant survival benefit observed in VITAL study for birtamimab-treated patients with AL amyloidosis at high risk for early mortality (Mayo Stage IV, HR=0.413, p=0.025, over 9 months)SPA agreement...